pyruvaldehyde has been researched along with Cardiovascular Diseases in 25 studies
Pyruvaldehyde: An organic compound used often as a reagent in organic synthesis, as a flavoring agent, and in tanning. It has been demonstrated as an intermediate in the metabolism of acetone and its derivatives in isolated cell preparations, in various culture media, and in vivo in certain animals.
methylglyoxal : A 2-oxo aldehyde derived from propanal.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
Excerpt | Relevance | Reference |
---|---|---|
"Diabetes mellitus is recognised as a risk factor driving atherosclerosis and cardiovascular mortality; even after the normalisation of blood glucose concentration, the event risk is amplified-an effect called "glycolytic memory"." | 2.82 | Dicarbonyl Stress in Diabetic Vascular Disease. ( Stratmann, B, 2022) |
"Candesartan treatment for 4 weeks significantly reduced these parameters." | 1.39 | Carbonyl stress induces hypertension and cardio-renal vascular injury in Dahl salt-sensitive rats. ( Chen, X; Endo, S; Guo, Q; Hu, C; Ito, S; Jiang, Y; Miyata, T; Mori, T; Nakayama, K; Nakayama, M; Ogawa, S; Ohsaki, Y; Yoneki, Y; Zhu, W, 2013) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (8.00) | 29.6817 |
2010's | 16 (64.00) | 24.3611 |
2020's | 7 (28.00) | 2.80 |
Authors | Studies |
---|---|
Rabbani, N | 3 |
Stratmann, B | 1 |
Schalkwijk, CG | 6 |
Stehouwer, CDA | 5 |
Khanam, A | 1 |
Ahmad, S | 1 |
Husain, A | 1 |
Rehman, S | 1 |
Farooqui, A | 1 |
Yusuf, MA | 1 |
Hanssen, NMJ | 4 |
Scheijen, JLJM | 4 |
Houben, AJHM | 1 |
van de Waarenburg, M | 2 |
Berendschot, TTJM | 1 |
Webers, CAB | 1 |
Reesink, KD | 1 |
van Greevenbroek, MMJ | 1 |
van der Kallen, C | 1 |
Schaper, NC | 1 |
Schram, MT | 1 |
Henry, RMA | 1 |
He, Y | 1 |
Zhou, C | 1 |
Huang, M | 1 |
Tang, C | 1 |
Liu, X | 1 |
Yue, Y | 1 |
Diao, Q | 1 |
Zheng, Z | 1 |
Liu, D | 1 |
Teraa, M | 1 |
Gremmels, H | 1 |
Verhaar, MC | 1 |
Jorsal, A | 1 |
Parving, HH | 1 |
Tarnow, L | 1 |
Rossing, P | 1 |
Westerink, J | 1 |
van der Graaf, Y | 1 |
Domingo-Espín, J | 1 |
Nilsson, O | 1 |
Bernfur, K | 1 |
Del Giudice, R | 1 |
Lagerstedt, JO | 1 |
Sankaralingam, S | 1 |
Ibrahim, A | 1 |
Rahman, MDM | 1 |
Eid, AH | 1 |
Munusamy, S | 1 |
Tezuka, Y | 1 |
Nakaya, I | 1 |
Nakayama, K | 2 |
Nakayama, M | 2 |
Yahata, M | 1 |
Soma, J | 1 |
Nigro, C | 1 |
Leone, A | 1 |
Fiory, F | 1 |
Prevenzano, I | 1 |
Nicolò, A | 1 |
Mirra, P | 1 |
Beguinot, F | 1 |
Miele, C | 1 |
Vulesevic, B | 1 |
Milne, RW | 1 |
Suuronen, EJ | 1 |
Thornalley, PJ | 2 |
Hansen, CS | 1 |
Jensen, TM | 1 |
Jensen, JS | 1 |
Nawroth, P | 1 |
Fleming, T | 1 |
Witte, DR | 1 |
Lauritzen, T | 1 |
Sandbaek, A | 1 |
Charles, M | 1 |
Fleischer, J | 1 |
Vistisen, D | 1 |
Jørgensen, ME | 1 |
Maessen, DE | 1 |
Stehouwer, CD | 1 |
Engelbertsen, D | 1 |
Vallejo, J | 1 |
Quách, TD | 1 |
Fredrikson, GN | 1 |
Alm, R | 1 |
Hedblad, B | 1 |
Björkbacka, H | 1 |
Rothstein, TL | 1 |
Nilsson, J | 1 |
Bengtsson, E | 1 |
Monnier, VM | 1 |
Sun, W | 1 |
Gao, X | 1 |
Sell, DR | 1 |
Cleary, PA | 1 |
Lachin, JM | 1 |
Genuth, S | 1 |
Kilhovd, BK | 1 |
Juutilainen, A | 1 |
Lehto, S | 1 |
Rönnemaa, T | 1 |
Torjesen, PA | 1 |
Hanssen, KF | 1 |
Laakso, M | 1 |
Chazov, EI | 1 |
Griffin, MD | 1 |
Wilson, LM | 1 |
Mok, YF | 1 |
Januszewski, AS | 1 |
Wilson, AM | 1 |
Karschimkus, CS | 1 |
Romas, E | 1 |
Lee, AB | 1 |
Godfrey, T | 1 |
Wong, M | 1 |
Clemens, L | 1 |
Jenkins, AJ | 1 |
Howlett, GJ | 1 |
Godfrey, L | 1 |
Xue, M | 1 |
Shaheen, F | 1 |
Geoffrion, M | 1 |
Milne, R | 1 |
Dmitriev, VA | 1 |
Oshchepkova, EV | 1 |
Titov, VN | 1 |
Balakhonova, TV | 1 |
Tripoten', MI | 1 |
Rogoza, AN | 1 |
Shiriaeva, IuK | 1 |
Chen, X | 1 |
Mori, T | 1 |
Guo, Q | 1 |
Hu, C | 1 |
Ohsaki, Y | 1 |
Yoneki, Y | 1 |
Zhu, W | 1 |
Jiang, Y | 1 |
Endo, S | 1 |
Ogawa, S | 1 |
Miyata, T | 1 |
Ito, S | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Intra-arterial Infusion of Autologous Bone Marrow Mononuclear Cells in Patients With Chronic Critical Limb Ischemia: a Randomized, Placebo-controlled Clinical Trial[NCT00371371] | Phase 1/Phase 2 | 160 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
Dietary Inducers of Glyoxalase-1 for Prevention and Early-stage Alleviation of Age Related Health Disorders Through Functional Foods.[NCT02095873] | Phase 1/Phase 2 | 32 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
Diabetes Control and Complications Trial (DCCT)[NCT00360815] | 1,441 participants | Interventional | 1983-08-31 | Completed | |||
Epidemiology of Diabetes Interventions and Complications (EDIC)[NCT00360893] | 1,441 participants (Actual) | Observational | 1994-04-30 | Active, not recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Aortal pulse wave velocity is measured by a non-invasive oscillometric device. (NCT02095873)
Timeframe: Week 0 and Week 8 (first intervention); Week 14 and Week 22 (second intervention)
Intervention | m/s (Median) | |
---|---|---|
Baseline | Post-8 weeks treatment | |
Glyoxalase 1 Inducer | 7.9 | 8.0 |
Placebo | 8.3 | 8.5 |
A standard 75 g glucose oGTT will be performed, as routinely used in clinical practice. Participants will be instructed to eat carbohydrate rich diet (> 150 g/day) for at least three days before the test, followed by an overnight fast. Participants will be instructed to have comparable macronutrient composition of the dinner before the respective study days in the metabolic unit. During the oGTT both capillary and venous blood samples will be collected after 0, 15, 30, 60, 90 and 120 min. To minimize the inconvenience of repeated blood tests during the oGTT, a venous cannula will be inserted, under sterile conditions, prior to the test, for blood sampling. (NCT02095873)
Timeframe: Week 0 and Week 8 (first intervention); Week 14 and Week 22 (second intervention)
Intervention | mM h (Mean) | |
---|---|---|
Baseline | Post-8 weeks treatment | |
Glyoxalase 1 Inducer | 10.8 | 9.9 |
Placebo | 11.0 | 10.6 |
After 20 min seated at rest, measurements are made with the subject seated and the left hand at heart level. Nail-fold capillaries in the dorsal skin of the third finger are visualized using a stereo microscope linked to a monochrome digital camera. Capillary density is defined as the number of capillaries per mm2 of nail-fold skin and is computed as the mean of 4 measurements. (NCT02095873)
Timeframe: Week 0 and Week 8 (first intervention); Week 14 and Week 22 (second intervention)
Intervention | number of capillaries per mm2 (Median) | |
---|---|---|
Baseline | Post-8 weeks treatment | |
Glyoxalase 1 Inducer | 115 | 125 |
Placebo | 119 | 128 |
Brachial artery FMD will be assessed. Ultrasound imaging of the brachial artery will be performed. Percent FMD will be calculated using the averaged minimum mean brachial artery diameter at baseline compared to the largest mean values obtained after either release of the forearm occlusion. (NCT02095873)
Timeframe: Week 0 and Week 8 (first intervention); Week 14 and Week 22 (second intervention)
Intervention | percentage of baseline value (Median) | |
---|---|---|
Baseline | Post-8 weeks treatment | |
Glyoxalase 1 Inducer | 0.17 | 0.12 |
Placebo | 0.18 | 0.26 |
9 reviews available for pyruvaldehyde and Cardiovascular Diseases
Article | Year |
---|---|
Dicarbonyl Stress in Diabetic Vascular Disease.
Topics: Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Glycation End Products, Advanced; | 2022 |
Methylglyoxal, a Highly Reactive Dicarbonyl Compound, in Diabetes, Its Vascular Complications, and Other Age-Related Diseases.
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Lactoylglutathione Lyase; Neopl | 2020 |
Glycation and Antioxidants: Hand in the Glove of Antiglycation and Natural Antioxidants.
Topics: Antigens, Neoplasm; Antioxidants; Cardiovascular Diseases; Deoxyglucose; Diabetes Mellitus, Type 2; | 2020 |
Glyoxalase system: A systematic review of its biological activity, related-diseases, screening methods and small molecule regulators.
Topics: Animals; Biological Products; Cardiovascular Diseases; Drug Evaluation, Preclinical; Enzyme Inhibito | 2020 |
Role of Methylglyoxal in Diabetic Cardiovascular and Kidney Diseases: Insights from Basic Science for Application into Clinical Practice.
Topics: Animals; Cardiovascular Diseases; Diabetes Complications; Humans; Kidney Diseases; Pyruvaldehyde | 2018 |
Dicarbonyl Stress at the Crossroads of Healthy and Unhealthy Aging.
Topics: Aging; Animals; Cardiovascular Diseases; Cells, Cultured; Cellular Senescence; Glycation End Product | 2019 |
Reducing methylglyoxal as a therapeutic target for diabetic heart disease.
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus; Glycation End Products, Advanced; Humans; Pyruv | 2014 |
Dicarbonyl stress in cell and tissue dysfunction contributing to ageing and disease.
Topics: Aging; Aldehydes; Cardiovascular Diseases; Deoxyglucose; Diabetes Mellitus; Glyoxal; Humans; Inflamm | 2015 |
The role of methylglyoxal and the glyoxalase system in diabetes and other age-related diseases.
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Angiopathies; D | 2015 |
2 trials available for pyruvaldehyde and Cardiovascular Diseases
Article | Year |
---|---|
The role of serum methylglyoxal on diabetic peripheral and cardiovascular autonomic neuropathy: the ADDITION Denmark study.
Topics: Adult; Aged; Cardiovascular Diseases; Cross-Sectional Studies; Denmark; Diabetes Mellitus, Type 2; D | 2015 |
Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes.
Topics: Adult; Arginine; Asymptomatic Diseases; Biomarkers; Biopsy; Cardiovascular Diseases; Carotid Artery | 2015 |
Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes.
Topics: Adult; Arginine; Asymptomatic Diseases; Biomarkers; Biopsy; Cardiovascular Diseases; Carotid Artery | 2015 |
Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes.
Topics: Adult; Arginine; Asymptomatic Diseases; Biomarkers; Biopsy; Cardiovascular Diseases; Carotid Artery | 2015 |
Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes.
Topics: Adult; Arginine; Asymptomatic Diseases; Biomarkers; Biopsy; Cardiovascular Diseases; Carotid Artery | 2015 |
14 other studies available for pyruvaldehyde and Cardiovascular Diseases
Article | Year |
---|---|
Methylglyoxal and glyoxalase 1-a metabolic stress pathway-linking hyperglycemia to the unfolded protein response and vascular complications of diabetes.
Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Humans; Hyperglycemia; Insulin R | 2022 |
Fasting and post-oral-glucose-load levels of methylglyoxal are associated with microvascular, but not macrovascular, disease in individuals with and without (pre)diabetes: The Maastricht Study.
Topics: Aged; Cardiovascular Diseases; Fasting; Female; Glucose Tolerance Test; Humans; Male; Middle Aged; P | 2021 |
Plasma Methylglyoxal Levels Are Associated With Amputations and Mortality in Severe Limb Ischemia Patients With and Without Diabetes.
Topics: Amputation, Surgical; Cardiovascular Diseases; Case-Control Studies; Diabetes Mellitus; Female; Glyc | 2021 |
Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease in Individuals With Type 1 Diabetes: A 12-Year Follow-up Study.
Topics: Adult; Cardiovascular Diseases; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Female; Follow-Up | 2017 |
Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease and Mortality in Individuals With Type 2 Diabetes.
Topics: Adult; Aged; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathi | 2018 |
Site-specific glycations of apolipoprotein A-I lead to differentiated functional effects on lipid-binding and on glucose metabolism.
Topics: Acetaldehyde; Animals; Apolipoprotein A-I; Blood Glucose; Cardiovascular Diseases; Cell Line; Choles | 2018 |
Methylglyoxal as a prognostic factor in patients with chronic kidney disease.
Topics: Aged; Arginine; Biomarkers; Cardiovascular Diseases; Deoxyglucose; Diabetic Nephropathies; Disease P | 2019 |
Low Levels of IgM Antibodies against an Advanced Glycation Endproduct-Modified Apolipoprotein B100 Peptide Predict Cardiovascular Events in Nondiabetic Subjects.
Topics: Aged; Aged, 80 and over; Antibodies; Apolipoprotein B-100; Atherosclerosis; Autoantibodies; B-Lympho | 2015 |
Increased serum levels of methylglyoxal-derived hydroimidazolone-AGE are associated with increased cardiovascular disease mortality in nondiabetic women.
Topics: Cardiovascular Diseases; Case-Control Studies; Cohort Studies; Diabetes Mellitus, Type 2; Female; Fi | 2009 |
[Progress in fundamental research: perspectives of cardiology].
Topics: Apelin; Biomarkers; Cardiology; Cardiovascular Diseases; Endothelium, Vascular; Humans; Intercellula | 2009 |
Thioflavin T fluorescence in human serum: correlations with vascular health and cardiovascular risk factors.
Topics: Adult; Amyloid beta-Peptides; Animals; Benzothiazoles; Biomarkers; Cardiovascular Diseases; Cattle; | 2010 |
Glycation of LDL by methylglyoxal increases arterial atherogenicity: a possible contributor to increased risk of cardiovascular disease in diabetes.
Topics: Animals; Aorta; Apolipoprotein B-100; Apolipoproteins E; Atherosclerosis; Cardiovascular Diseases; C | 2011 |
[Nonspecific inflammation and structural changes in the arteries of hypertensive males at high and moderate risk for cardiovascular events].
Topics: Adult; Aged; Ankle Brachial Index; Blood Pressure; C-Reactive Protein; Cardiovascular Diseases; Elas | 2012 |
Carbonyl stress induces hypertension and cardio-renal vascular injury in Dahl salt-sensitive rats.
Topics: Albuminuria; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; B | 2013 |